Here’s a great rendition

Forwarded this email? Subscribe here for more

Since Fauci just testified (in closed session) before Congress, I provide the evidence of some well-documented crimes he committed

The risk of GOF was our risk, not his–no doubt he received the best countermeasures, while suppressing them for the public. Since he had already tested them.


Below are three of the ways Dr. Fauci stopped the use of hydroxychloroquine for COVID, even though his agency had proven that it worked in tissue culture to kill the earlier SARS virus:

First method

  • After earlier delays, starting in May 2020, Fauci’s NIAID began a trial in outpatients, using hydroxychloroquine plus azithromycin. But NIAID only enrolled 20 patients, after planning for 2,000.
  • NIAID reduced the planned duration of followup from 24 weeks to 13 days post treatment. NIAID cancelled the study after only 5 weeks, claiming that the reason was inadequate enrollments, even though NIAID had 11 study sites to enroll patients.
  • I reviewed the consent document for the trial, and concluded that one way enrollments were discouraged was by making the drug appear to be very dangerous to potential subjects in the document.
  • Fauci is a master at gaming the system—telling Congress and the public he tried to do an outpatient study of HCQ, but no one wanted it. Not his fault it had to be quickly cancelled. [Did the subjects do too well?]. OTOH, he claimed that hundreds of thousands were begging to take part in vaccine trials.

Second method

Third method

Here is the proof he knew the drug would work—and my guess is he was taking it himself. Fauci’s NIAID published the following in 2014.

Here is the abstract:

Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

Below you can see in this paper that both drugs, chloroquine and hydroxychloroquine, killed BOTH SARS-1 and MERS viruses in tissue culture:


In order to prevent the emergence of a novel virus from growing into a pandemic or established human pathogen, it is critical that public health officials and clinicians be able to diagnose the infection, control its spread, and treat those afflicted. First and foremost, we need more countermeasures that can be used for the early phase of an epidemic to provide an immediate treatment response while more-appropriate therapies are being developed. Given the time and costs associated with licensure of novel therapeutics, one feasible and rapid response is through repurposing of existing clinically developed products. Repurposing of approved drugs has several advantages, including known safety/tolerability profiles, availability, lower cost, and familiarity of clinicians in working with these drugs. Supplying the international community with robust sets of in vitro and in vivo data on potential drugs for treatment of emerging viral diseases continues to be a high priority, as it will allow clinicians to make educated decisions on clinically available drugs for testing in intervention trials.

The next step was to test the drugs in mice. I have not seen those results published. The authors wrote: “Protection studies using a mouse-adapted SARS-CoV will be performed to identify the in vivo efficacy of targeted drugs from our screen.”

But Fauci had his reasons for covering up the lab origin of the pandemic, and one of those reasons was a plan to blame humans and climate change for the pandemic.

Very well planned? I’d say yes. Does it display a level of evil that it is hard to believe exists, especially in our top (and best-paid) health official? Yes.

If you want to unravel the pandemic and the great preset, rendition Fauci to a rat-infested jail in Timbuktu, and see how long it takes him to fess up in exchange for being released. After all, renditions are something we know how to do really well.

Let’s do it when it counts.

Meryl Nass

Get the latest Tap posts emailed to you daily

One Response to “Here’s a great rendition”

  1. Belyi says:

    No need to send him to Timbuktu because I understand he has already been dealt with. What we’re seeing, when we’re seeing him, is either a body double or a clone.